Table 3.
Trial location and sponsor of TCM interventional studies.
| Parameter | Number/total number (%) | |||
|---|---|---|---|---|
| All Trials (N = 1270) | Oct 2000–Sep 2005 (N = 95) | Oct 2005–Sep 2010 (N = 396) | Oct 2010–Sep 2015 (N = 779) | |
| Region, N | ||||
| Africa | 8/1270 (0.6) | 1/95 (1.1) | 1/396 (0.3) | 6/779 (0.8) |
| Asia-Pacific | 670/1270 (52.8) | 28/95 (29.5) | 185/396 (46.7) | 457/779 (58.7) |
| Central and South America | 52/1270 (4.1) | 5/95 (5.3) | 24/396 (6.1) | 23/779 (3.0) |
| Europe | 195/1270 (15.4) | 19/95 (20.0) | 81/396 (20.5) | 95/779 (12.2) |
| Middle East | 28/1270 (2.2) | 0 | 10/396 (2.5) | 18/779 (2.3) |
| North America | 362/1270 (28.5) | 78/95 (82.1) | 140/396 (35.4) | 144/779 (18.5) |
| Lead sponsor, N | ||||
| Industry | 63/1270 (5.0) | 5/95 (5.3) | 13/396 (3.3) | 45/779 (5.8) |
| NIH | 55/1270 (4.3) | 46/95 (48.4) | 7/396 (1.8) | 2/779 (0.3) |
| US Fed (non-NIH) | 28/1270 (2.2) | 1/95 (1.1) | 12/396 (3.0) | 15/779 (1.9) |
| Othera | 1124/1270 (88.5) | 43/95 (45.3) | 364/396 (91.9) | 717/779 (92.0) |
| Country of lead ponsor b , N | ||||
| Chinac | 527/1270 (41.5) | 14/95 (14.7) | 142/396 (35.9) | 371/779 (47.6) |
| United States | 360/1270 (28.3) | 76/95 (80.0) | 140/396 (35.4) | 144/779 (18.5) |
| Korea | 58/1270 (4.6) | 1/95 (1.1) | 13/396 (3.3) | 44/779 (5.6) |
| Germany | 42/1270 (3.3) | 1/95 (1.1) | 19/396 (4.8) | 22/779 (2.8) |
| Canada | 39/1270 (3.1) | 3/95 (3.2) | 17/396 (4.3) | 19/779 (2.4) |
| Brazil | 35/1270 (2.8) | 2/95 (2.1) | 10/396 (2.5) | 23/779 (3.0) |
| Israel | 20/1270 (1.6) | 0 | 8/396 (2.0) | 12/779 (1.5) |
| Spain | 17/1270 (1.3) | 1/95 (1.1) | 3/396 (0.8) | 13/779 (1.7) |
| United Kingdom | 16/1270 (1.3) | 2/95 (2.1) | 7/396 (1.8) | 7/779 (0.9) |
| Sweden | 15/1270 (1.2) | 0 | 8/396 (2.0) | 7/779 (0.9) |
aFor the TCM trials, further manual classification of the “other” lead sponsor group found that this group was all composed of academic institutions/medical centers. bOnly listing the top 10 countries of lead sponsor. cIncluding Taiwan and Hong Kong.